Abstract Number: 2284 • 2017 ACR/ARHP Annual Meeting
Use of Biological Therapies in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events with Biologic Therapies (BIOBADASER)
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The advent of new biological drugs has changed the prognosis and…Abstract Number: 2291 • 2017 ACR/ARHP Annual Meeting
Three Treatment Strategies in Recent Onset DMARD Naive Juvenile Idiopathic Arthritis: First Results of Clinical Outcome after 24 Months
Background/Purpose: The BeSt treatment strategy for children with juvenile idiopathic arthritis (JIA) has not been determined. The aim of the BeSt for Kids study was…Abstract Number: 274 • 2014 ACR/ARHP Annual Meeting
Treatment Prescribing Patterns in a Cohort of Patients with Juvenile Idiopathic Arthritis (JIA). Data from the Childhood Arthritis Prospective Study
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a heterogenous disease, classified according to the International League of Associations for Rheumatology (ILAR). Initial treatment is based largely…Abstract Number: 1172 • 2012 ACR/ARHP Annual Meeting
Delineating the Role of Multiple Corticosteroid Joint Injections in the Management of Juvenile Idiopathic Arthritis in the Biologic Era
Background/Purpose: Intra-articular corticosteroid injection (IACI) therapy in juvenile idiopathic arthritis (JIA) is generally considered for the treatment of children with arthritis in a small number…
ACR Meeting Abstracts